Mylan Inks $264M Deal Ending EpiPen Class Price-Hike Suit
Health care company Viatris — formerly known as Mylan — said Monday that it has agreed to a $264 million settlement to resolve class action claims that it conspired with Pfizer Inc....To view the full article, register now.
Already a subscriber? Click here to view full article